Close Menu

NEW YORK – Molecular diagnostics firm NeuMoDx will collaborate with SelfScreen, a Netherlands-based company, to commercialize a human papillomavirus screening test.

SelfScreen, a spinout of VU University Medical Center in Amsterdam, has developed a real-time PCR-based HPV screening test that detects 15 high-risk genotypes that can cause cervical cancer.

Under the agreement, SelfScreen will oversee the regulatory processes to obtain CE-IVD marking for the assay on the NeuMoDx 288 and NeuMoDx 96 sample-to-result systems, and NeuMoDx will manufacture and sell the assay.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.

According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.

New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.

In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
04
Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).